The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension

It is suggested that this new biochemical marker, PTX3, might be better and more specific marker for endothelial dysfunction, than hs-CRP, so it may be assumed that candesartan has a more potent action in reversing endothelium dysfunction and that it offers a higher vascular protection than other classes of antihypertensive drugs.